Neurocrine Biosciences (NBIX) Inventory (2017 - 2026)

Neurocrine Biosciences (NBIX) has reported Inventory for 10 consecutive years, with $104.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Inventory rose 83.13% year-over-year to $104.2 million; the trailing twelve-month figure through Jun 2026 stood at $104.2 million (up 83.13% YoY), and the FY2025 full-year result was $69.0 million, up 20.21% from the prior year.
• Inventory grew to $104.2 million in Q2 2026 per NBIX's latest filing, from $64.5 million in the prior quarter.
• Across five years, Inventory topped out at $104.2 million in Q2 2026 and bottomed at $28.8 million in Q3 2023.
• Historically, Inventory has averaged $48.2 million across 5 years, with a median of $40.4 million in 2023.
• The sharpest annual moves came in 2023 and 2026: Inventory retreated 22.16% in 2023, then jumped 83.13% in 2026.
• Over 5 years, Inventory stood at $35.1 million in 2022, then advanced by 9.12% to $38.3 million in 2023, then soared by 49.87% to $57.4 million in 2024, then gained by 20.21% to $69.0 million in 2025, then jumped by 51.01% to $104.2 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $104.2 million, $64.5 million, and $69.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.